Sight Sciences downgraded to Underperform at BofA on Medicare uncertainty
The Fly

Sight Sciences downgraded to Underperform at BofA on Medicare uncertainty

As previously reported, BofA analyst Craig Bijou downgraded Sight Sciences to Underperform from Neutral with a price target of $4.50, down from $10, after the company guided Q3 revenue 18% below Street consensus at the midpoint as the uncertainty from proposed Medicare coverage changes for surgical glaucoma products has hurt ordering activity. The firm sees limited upside potential for the stock until there is clarity on the finalized local coverage determination, or LCD, the analyst tells investors.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on SGHT:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App